Dermatology billing is among the most procedure-intensive outpatient specialties. In a single patient visit, a dermatologist may perform a comprehensive skin examination, a punch biopsy of a suspicious lesion, cryotherapy for multiple actinic keratoses, and a shave removal of a benign lesion — each service carrying its own CPT code, its own documentation standard, and its own NCCI bundling consideration. Coding one element incorrectly in that scenario creates a cascade of bundling edits, modifier requirements, and potential denials.

In 2026, the dermatology coding landscape changed in ways that directly affect revenue. The AMA updated biopsy code descriptors to require explicit documentation of technique specificity — tangential, punch, or incisional. Destruction codes now require documentation of the specific method used. And skin substitutes underwent a major CMS reimbursement restructuring — with some advanced wound products facing up to a 90% reduction from prior payment rates — making accurate product classification and HCPCS code mapping more financially consequential than in any recent year.

This guide covers the complete dermatology billing and coding framework for 2026.

---

Part 1: Evaluation and Management in Dermatology

E/M Code Selection for Dermatology Visits

Standard outpatient E/M codes (99202–99215) apply to dermatology visits based on Medical Decision Making (MDM) or total time.

Code	MDM Level	Minimum Time
99202	Straightforward (new patient)	15–29 minutes
99203	Low complexity (new patient)	30–44 minutes
99204	Moderate complexity (new patient)	45–59 minutes
99205	High complexity (new patient)	60–74 minutes
99211	Minimal (established — staff visit)	—
99212	Straightforward (established)	10–19 minutes
99213	Low complexity (established)	20–29 minutes
99214	Moderate complexity (established)	30–39 minutes
99215	High complexity (established)	40–54 minutes

Time-based billing in dermatology: If documented time is 39 minutes or less, the visit must be coded 99214 — not 99215, regardless of the complexity of the skin findings. AI-powered claim review systems in 2026 are specifically flagging time-code mismatches in dermatology.

Modifier 25 — The Highest-Value Modifier in Dermatology

Modifier 25 (significant, separately identifiable E/M on same day as procedure) is the most frequently missed revenue opportunity in dermatology billing.

When a patient comes in for a scheduled procedure but the encounter also includes a significant, separately identifiable evaluation — such as reviewing new lesions not originally scheduled, evaluating a systemic skin condition, or changing a treatment regimen — both the E/M and the procedure may be billed with Modifier 25 on the E/M.

Documentation requirement: The medical record must contain a complete E/M note that stands independently from the procedure note. A line that says “skin exam performed” within the procedure note does not support a separately billed E/M.

⚠️ Missing Modifier 25 is one of the highest-value revenue leakage points in dermatology billing. Train every dermatologist to document the evaluation and the procedure as separate components when both are clinically performed.

---

Part 2: Skin Biopsy Codes — Technique Specificity Required in 2026

The Biopsy Code Family

Code	Technique	Application
11102	Tangential biopsy — first lesion	Shave, saucerization, curette technique
+11103	Tangential biopsy — each additional lesion	Add-on for each additional same-technique lesion
11104	Punch biopsy — first lesion	Circular punch tool
+11105	Punch biopsy — each additional lesion	Add-on
11106	Incisional biopsy — first lesion	Wedge or incisional technique
+11107	Incisional biopsy — each additional lesion	Add-on

2026 Documentation Requirement: Technique Must Be Specified

Effective January 1, 2026, biopsy code descriptors require explicit documentation of the technique used. The CPT code selection must match the documented technique — tangential, punch, or incisional. Biopsy notes that do not specify the technique create a documentation-to-code mismatch that creates audit risk.

Update your EHR biopsy procedure templates immediately to include a required field for technique selection. The template should not allow submission of a biopsy note without specifying: tangential (shave/saucerization), punch, or incisional.

Additional documentation required for biopsies:

• Lesion size measured before anesthesia administration
• Anatomic site
• Clinical description of the lesion (color, borders, size, morphology)

⚠️ NCCI bundling rule: If a biopsy and an excision are performed on the same lesion during the same session, code only the excision — the biopsy is bundled. Billing both on the same lesion is one of the most common dermatology NCCI edit violations.

Pathology Coding Alongside Biopsy

When biopsy specimens are sent to pathology:

• 88304 — Skin, biopsy (histologic examination, Level IV — most common for skin biopsies)
• 88305 — Complex specimens requiring additional interpretation (Level V)

⚠️ Include pathology reports with claims for 88304/88305 to prevent automatic denials. Document specimen type and note if special stains or immunohistochemistry were used.

---

Part 3: Lesion Destruction — Method Specificity Required in 2026

Premalignant Lesion Destruction (Actinic Keratoses)

Code	Description
17000	Destruction of premalignant lesion — first lesion
+17003	Each additional lesion, 2nd through 14th
17004	Destruction of 15 or more premalignant lesions

⚠️ Single most common destruction coding error: Billing 17000 multiple times instead of using the add-on structure. Five actinic keratoses = 17000 × 1 + 17003 × 4 — NOT 17000 × 5. Billing the primary code repeatedly is automatic denial.

Benign Lesion Destruction

Code	Description
17110	Destruction of benign lesions (warts, molluscum, etc.) — up to 14 lesions
17111	Destruction of 15 or more benign lesions

Malignant Lesion Destruction

Malignant lesion destruction is coded by anatomic site first, then lesion size:

• 17260–17266 — Trunk, arms, legs
• 17270–17276 — Scalp, neck, hands, feet, genitalia
• 17280–17286 — Face, ears, eyelids, nose, lips, mucous membrane

2026 Requirement: Document the Destruction Method

Effective 2026, destruction codes require documentation of the specific technique used:

• Cryosurgery (liquid nitrogen)
• Electrosurgery / electrodesiccation
• Laser ablation
• Chemical destruction (trichloroacetic acid, cantharidins, etc.)

Generic documentation such as “lesion destroyed” without method specification creates a documentation gap that supporting 2026 CPT descriptors. Update your procedure note templates to require method selection.

Payers Now Require Medical Necessity for Benign Destruction

In 2026, payers are increasingly requiring documented medical necessity for benign lesion destruction. Cosmetic intent is not a covered indication. The clinical note must document why destruction was medically necessary — bleeding, irritation, functional impairment, or patient distress with clinical justification.

⚠️ A claim for 17110 or 17111 with documentation indicating the lesion was removed for cosmetic reasons will be denied as non-covered. Retrain providers to document clinical necessity, not cosmetic request.

---

Part 4: Skin Excision Codes

Excision codes are selected based on four required documentation elements:

1. Lesion diameter — measured before excision, not including margins
2. Surgical margins — the additional tissue excised beyond the lesion
3. Final excised diameter — lesion plus margins (this determines the CPT code)
4. Benign vs. malignant — determines the code family

Benign Excision Codes (11400–11446)

Code Range	Anatomic Site
11400–11406	Trunk, arms, legs
11420–11426	Scalp, neck, hands, feet, genitalia
11440–11446	Face, ears, eyelids, nose, lips, mucous membrane

Within each range, the final digit indicates lesion size:

• 0 = 0.5 cm or less
• 1 = 0.6–1.0 cm
• 2 = 1.1–2.0 cm
• 4 = 2.1–3.0 cm
• 5 = 3.1–4.0 cm
• 6 = over 4.0 cm

Malignant Excision Codes (11600–11646)

Same anatomic site and size structure as benign excisions, in the 11600 series. The distinction between benign and malignant is determined by the pathology report — not the pre-surgical clinical impression.

Wound Repair After Excision

Simple closure is NOT separately billed — it is included in the excision code.

Intermediate or complex closure IS separately billable when documented:

• 12031–12057 — Intermediate repair (layered closure, debridement)
• 13100–13153 — Complex repair (scar revision, rotational closure)

⚠️ Many billing teams leave wound repair off excision claims assuming it is always bundled. Intermediate and complex closures are separately payable — document the specific closure technique to support separate billing.

---

Part 5: Mohs Surgery — 2026 Documentation Updates

Mohs Surgery CPT Codes

Code	Description
17311	Mohs micrographic surgery — first stage, up to 5 tissue blocks
+17312	Each additional stage, up to 5 tissue blocks (add-on)
17313	First stage, head, neck, hands, feet, genitalia, face
+17314	Each additional stage — above sites
+17315	Each additional block beyond 5, any stage

Mohs codes include mapping, pathology interpretation, and wound assessment. They do NOT include reconstruction — reconstruction is separately billed with appropriate repair codes.

2026 Mohs Documentation Updates

Pathology reports must align with 2026 CAP (College of American Pathologists) standards before reconstruction codes can be billed on the same date.

Mohs operative notes in 2026 must document:

• Number of stages performed
• Number of tissue blocks per stage
• Clear margin assessment per stage
• Wound description after final stage
• Whether reconstruction was performed and by whom

⚠️ Mohs staging codes saw documentation requirement updates for 2026 affecting operative notes and pathology report standards. Practices using 2025 Mohs operative templates without updating for 2026 requirements are at risk of systematic claim rejections.

---

Part 6: Skin Substitutes — Major 2026 Reimbursement Change

This is the most financially impactful 2026 change for dermatology practices that use advanced wound products.

CMS reclassified skin substitutes from biologicals (average sales price methodology) to incident-to supplies for 2026. The new payment structure sets a single national rate of approximately $127.28 per square centimeter for Medicare skin substitute claims, rather than using product-specific average sales price calculations.

For practices using high-cost advanced wound products — particularly amniotic membrane products — this represents a reimbursement reduction of up to 90% compared to 2025 rates for certain products.

What this means operationally:

• Map every skin substitute product your practice uses to its current HCPCS code
• Verify the 2026 Medicare payment rate for each product under the new classification
• Re-evaluate the financial viability of each advanced wound product in your formulary
• For commercial payers: many commercial payers benchmark to Medicare; this change may ripple into commercial reimbursement

---

Part 7: Acne Surgery — Updated 2026 CPT Descriptor

CPT 10040 was updated in 2026 to change the code name and descriptor:

Previous (2025): 10040 — “Acne surgery” 2026: 10040 — “Extraction of inflammatory or non-inflammatory acne lesions”

The procedure and billing have not changed — only the descriptor language. However, operatve note templates and superbills that reference “acne surgery” as the procedure name should be updated to reflect the current 2026 terminology.

⚠️ Payers may take 60–90 days to fully adopt new CPT descriptor language in their claim editing systems. Have a rejection management protocol for any 10040 claims denied during the transition period.

---

Part 8: Common ICD-10 Codes in Dermatology

Code	Description
L57.0	Actinic keratosis
C44.x	Malignant neoplasm of skin (various sites)
D22.x	Melanocytic nevi (moles, by site)
D23.x	Other benign neoplasm of skin
L70.0	Acne vulgaris
L20.9	Atopic dermatitis, unspecified
L30.9	Dermatitis, unspecified
B07.0	Plantar wart
B07.8	Other viral warts
B08.1	Molluscum contagiosum
L82.1	Seborrheic keratosis
L91.0	Hypertrophic scar / keloid
C43.x	Melanoma of skin (by site)
D04.x	Carcinoma in situ of skin
Z12.83	Encounter for screening for malignant neoplasm of skin

---

Part 9: Key Modifiers in Dermatology

Modifier	When to Use
25	Significant E/M on same day as procedure — document separately
59	Distinct procedural service — bypass NCCI bundling when procedures are genuinely separate
51	Multiple procedures same session (secondary procedures)
77	Repeat procedure by same physician
RT / LT	Right or left side — for bilateral anatomic procedures

Modifier 59 in dermatology — most critical use cases:

• Billing 17000 (AK destruction) AND 17110 (benign lesion destruction) on the same date — requires Modifier 59 on one code to override the NCCI bundling edit
• Billing a biopsy AND a destruction on different lesions the same day — Modifier 59 on the secondary service distinguishes them as separate procedures

---

Part 10: Top Denial Patterns in Dermatology

1. Biopsy and Excision Billed Together on Same Lesion

Results in CO-97 bundling denial — excision includes the biopsy.

Fix: Code only the excision when both biopsy and definitive treatment of the same lesion occur in the same session.

2. Wrong Destruction Add-On Structure

Billing 17000 × 5 for five AKs instead of 17000 × 1 + 17003 × 4.

Fix: Post the correct add-on structure in every biller’s reference: 17000 first, 17003 × (n-1) for each additional, 17004 replaces both when 15+ lesions.

3. Biopsy Technique Not Documented

Using 11104 (punch biopsy) when the procedure note does not specify “punch.”

Fix: Update all biopsy EHR templates to require technique field: tangential/shave, punch, or incisional.

4. Benign Destruction Without Medical Necessity

17110 denied as cosmetic — documentation says “patient requested removal.”

Fix: Document clinical necessity: bleeding, irritation, functional impairment, or clinical concern. Never document cosmetic rationale.

5. Missing Modifier 25 on E/M With Procedure

E/M denied as included in procedure payment when Modifier 25 was not applied.

Fix: Any E/M performed the same day as a procedure requires Modifier 25 when the E/M is separately identifiable. Train providers and billers.

6. Skin Substitute Billed at 2025 ASP Rate

Revenue shortfall because billing system was not updated for 2026 incident-to supply classification.

Fix: Update all skin substitute HCPCS codes and payment expectations to reflect the 2026 $127.28/cm² national rate.

7. Excision Missing Required Measurements

11400-level excision denied because lesion size, margins, or final excised diameter not documented.

Fix: Require all four measurements in every excision note: pre-excision lesion size, surgical margins, final excised diameter, benign vs. malignant.

8. Layered Closure Not Billed Separately

Intermediate repair (12031+) left off excision claim — assumed to be bundled.

Fix: Document the specific closure technique. Intermediate and complex closures are separately billable — train coders to identify and bill them.

---

What Your Dermatology Practice Should Do Right Now

2026 code updates:

• Update all biopsy EHR templates to require technique specification (tangential/punch/incisional)
• Update all destruction procedure templates to require method documentation (cryosurgery/electro/laser/chemical)
• Update the 10040 acne code descriptor in superbills and templates
• Review and re-price all skin substitute products against the 2026 $127.28/cm² Medicare rate

Documentation compliance:

• Audit 30 recent biopsy claims for technique documentation — if any do not specify the technique, update the template
• Audit benign destruction claims for documented medical necessity — remove any cosmetic language
• Confirm all Mohs operative notes include stage count, block count, margin status, and wound description

Revenue protection:

• Run a 50-claim audit for NCCI bundling violations — biopsy + excision same lesion, 17000 + 17110 without Modifier 59
• Add NCCI edit checking to your pre-submission workflow
• Implement Modifier 25 tracking — every E/M billed same day as procedure should have a review step

At ClaimsXperts, we work with dermatology practices on biopsy technique documentation, NCCI bundling compliance, destruction coding structure, and full-cycle revenue cycle management.

Contact us today at https://www.rcmmasters.com/#contactus

ClaimsXperts is a Revenue Cycle Management company based in Frisco, TX.